(Q40414815)

English

Fever-range whole-body thermal therapy combined with cisplatin, gemcitabine, and daily interferon-alpha: a description of a phase I-II protocol

scientific article published on December 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Fever-range whole-body thermal therapy combined with cisplatin, gemcitabine, and daily interferon-alpha: a description of a phase I-II protocol (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

1 reference

based on heuristic

inferred from title

author name string

Joan M C Bull

1

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Glenna L Scott

2

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Frederick R Strebel

3

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Verne L Nagle

4

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Dwight Oliver

5

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Michael Redwine

6

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

R Wanda Rowe

7

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Chul W Ahn

8

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Steven M Koch

9

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

publication date

1 December 2008

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

International Journal of Hyperthermia

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

649-662

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

The importance of schedule in whole body thermochemotherapy

1 reference

https://api.crossref.org/works/10.1080%2F02656730802104740

21 January 2018

Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell

1 reference

https://api.crossref.org/works/10.1080%2F02656730802104740

21 January 2018

Interferon-alpha in tumor immunity and immunotherapy

1 reference

https://api.crossref.org/works/10.1080%2F02656730802104740

21 January 2018

Protocols for simulating the thermal component of fever: preclinical and clinical experience.

1 reference

https://api.crossref.org/works/10.1080%2F02656730802104740

21 January 2018

Sometimes size doesn't matter: reevaluating RECIST and tumor response rate endpoints

1 reference

https://api.crossref.org/works/10.1080%2F02656730802104740

21 January 2018

RECIST revisited: a review of validation studies on tumour assessment

1 reference

https://api.crossref.org/works/10.1080%2F02656730802104740

21 January 2018

Some practical improvements in the continual reassessment method for phase I studies.

1 reference

https://api.crossref.org/works/10.1080%2F02656730802104740

21 January 2018

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1080%2F02656730802104740

21 January 2018

Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine

1 reference

https://api.crossref.org/works/10.1080%2F02656730802104740

21 January 2018

A phase I study of fever-range whole body hyperthermia (FR-WBH) in patients with advanced solid tumours: correlation with mouse models

1 reference

https://api.crossref.org/works/10.1080%2F02656730802104740

21 January 2018

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

1 reference

https://api.crossref.org/works/10.1080%2F02656730802104740

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1080%2F02656730802104740

21 January 2018

Improvement of tumor oxygenation by mild hyperthermia

1 reference

https://api.crossref.org/works/10.1080%2F02656730802104740

21 January 2018

Implications of increased tumor blood flow and oxygenation caused by mild temperature hyperthermia in tumor treatment

1 reference

https://api.crossref.org/works/10.1080%2F02656730802104740

21 January 2018

Delivery of novel therapeutic agents in tumors: physiological barriers and strategies

1 reference

https://api.crossref.org/works/10.1080%2F02656730802104740

21 January 2018

The Eugene M. Landis Award Lecture 1996. Delivery of molecular and cellular medicine to solid tumors

1 reference

https://api.crossref.org/works/10.1080%2F02656730802104740

21 January 2018

Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942.

1 reference

https://api.crossref.org/works/10.1080%2F02656730802104740

21 January 2018

Use of mild, whole body hyperthermia in cancer therapy.

1 reference

https://api.crossref.org/works/10.1080%2F02656730802104740

21 January 2018

Tumor cell apoptosis, lymphocyte recruitment and tumor vascular changes are induced by low temperature, long duration (fever-like) whole body hyperthermia.

1 reference

https://api.crossref.org/works/10.1080%2F02656730802104740

21 January 2018

Fever-range thermal stress promotes lymphocyte trafficking across high endothelial venules via an interleukin 6 trans-signaling mechanism.

1 reference

https://api.crossref.org/works/10.1080%2F02656730802104740

21 January 2018

Emerging evidence indicates that physiologically relevant thermal stress regulates dendritic cell function

1 reference

https://api.crossref.org/works/10.1080%2F02656730802104740

21 January 2018

Signals required for programming effector and memory development by CD8+ T cells

1 reference

https://api.crossref.org/works/10.1080%2F02656730802104740

21 January 2018

Dendritic cells generated in the presence of GM-CSF plus IL-15 prime potent CD8+ Tc1 responses in vivo

1 reference

https://api.crossref.org/works/10.1080%2F02656730802104740

21 January 2018

Rapamycin inhibits GM-CSF-induced neutrophil migration

1 reference

https://api.crossref.org/works/10.1080%2F02656730802104740

21 January 2018

Differential regulation of neutrophil chemotaxis to IL-8 and fMLP by GM-CSF: lack of direct effect of oestradiol

1 reference

https://api.crossref.org/works/10.1080%2F02656730802104740

21 January 2018

Improving the capture of adverse event data in clinical trials: the role of the International Atomic Energy Agency.

1 reference

https://api.crossref.org/works/10.1080%2F02656730802104740

21 January 2018

Identifiers

10.1080/02656730802104740

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40414815&oldid=1897273784"